<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=description content="Speaking to reporters on Thursday in Abuja, Director-General of NAFDAC, Dr. Mojisola Adeyeye, said the agency gave the approval after subjecting the vaccine to various tests. Adeyeye said NAFDAC got the dossier of the vaccine a week ago, and its safety committee went to work immediately to evaluate its safety and efficacy for Nigerians."><meta name=author content="Hettie Henneman"><meta name=generator content="Hugo 0.98.0"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=robots content="index,follow,noarchive"><link rel=stylesheet href=https://assets.cdnweb.info/hugo/base16/css/style.css type=text/css><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Source+Code+Pro:400,700" type=text/css><link rel=alternate href=./index.xml type=application/rss+xml title=VivaDash><title>NAFDAC Approves AstraZeneca COVID-19 Vaccine For Use - VivaDash</title></head><body><header><div class="container clearfix"><a class=path href=./index.html>[VivaDash]</a>
<span class=caret># _</span><div class=right></div></div></header><div class=container><main role=main class=article><article class=single itemscope itemtype=http://schema.org/BlogPosting><div class=meta><span class=key>published on</span>
<span class=val><time itemprop=datePublished datetime=2024-06-14>June 14, 2024</time></span>
<span class=key>in</span>
<span class=val><a href=./categories/post>Post</a></span></div><h1 class=headline itemprop=headline>NAFDAC Approves AstraZeneca COVID-19 Vaccine For Use</h1><section class=body itemprop=articleBody><img src=https://cdn.statically.io/img/www.naijanews.com/wp-content/uploads/2020/12/NAFDAC-DG-Prof-Mojisola-Adeyeye.jpg style=margin:auto;display:block;text-align:center;max-width:100%;height:auto><h2>The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the Oxford/AstraZeneca COVID-19 vaccine for use in Nigeria.</h2><p>Speaking to reporters on Thursday in Abuja, Director-General of NAFDAC, Dr. Mojisola Adeyeye, said the agency gave the approval after subjecting the vaccine to various tests.</p><p>Adeyeye said NAFDAC got the dossier of the vaccine a week ago, and its safety committee went to work immediately to evaluate its safety and efficacy for Nigerians.</p><p>She noted that the vaccine could be stored in two to eight degrees Centigrade, adding that there were three additional vaccines undergoing evaluation.</p><p>Adeyeye asserted that&nbsp;the evaluation of the vaccine shows that the vaccine is effective against the United Kingdom variant of the virus which has been reported in Nigeria.</p><p>The NAFDAC DG stressed that the South African variant has not been reported in Nigeria, while the agency has over 30 herbal medicines undergoing review for listing.</p><p>Naija News reports that the Oxford/AstraZeneca vaccine, also known as ChAdOx1 nCoV-19, or AZD1222, is a viral vector vaccine and was recently approved by the World Health Organisation (WHO) for emergency use.</p><p>According to WHO, the AZD1222 vaccine against COVID-19 has an efficacy of 63.09% against symptomatic SARS-CoV-2 infection.</p><p>The health organisation said no substantive data are available related to the impact of AZD1222 on transmission or viral shedding.</p><p>In the meantime, WHO asks citizens to maintain and strengthen public health measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds, and ensuring good ventilation.</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmivp6x7r63Io5innaeoe6S7zGhpaWphZH1ze5BxZqeZlpmupHnAqaerp6aawG6t0q2pmrKVo7KkrYycpq%2BhlGJ%2BennVmpqcoZ6aeqe70WasrJ1f</p></section></article></main></div><footer><div class=container><span class=copyright>&copy; 2024 VivaDash - <a rel=license href=http://creativecommons.org/licenses/by/4.0/>CC BY 4.0</a></span></div></footer><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/banner.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/tracking_server_1.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>